Anti-NMDAR encephalitis in Crohn's disease undergoing long-term infliximab treatment: A case report.

Oh, Shin Ju; Kwon, Young Nam; Lee, Chang Kyun; Lee, Jin San

Oh, Shin Ju; Kwon, Young Nam; Lee, Chang Kyun; Lee, Jin San.

Afiliação

Oh SJ; Center for Crohn's and Colitis, Department of Gastroenterology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, South Korea.
Kwon YN; Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Lee CK; Center for Crohn's and Colitis, Department of Gastroenterology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, South Korea.
Lee JS; Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, South Korea.

Front Immunol ; 13: 957575, 2022.

Article em En | MEDLINE | ID: mdl-36389693

Assuntos

Encefalite Antirreceptor de N-Metil-D-Aspartato; Doença de Crohn; Masculino; Humanos; Recém-Nascido; Adulto; Encefalite Antirreceptor de N-Metil-D-Aspartato/diagnóstico; Infliximab/efeitos adversos; Doença de Crohn/complicações; Doença de Crohn/tratamento farmacológico; Estudos de Casos e Controles; Inibidores do Fator de Necrose Tumoral; Fator de Necrose Tumoral alfa/uso terapêutico

Palavras-chave

Crohn 's disease; anti-N-methyl-D-aspartate; anti-tumor necrosis factor-α; autoimmune encephalitis; infliximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn / Encefalite Antirreceptor de N-Metil-D-Aspartato Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans / Male / Newborn Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google